secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001493152-24-032517
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MangoRx reports H1 2024 revenue up 56% YoY to $377K; shareholders' equity jumps 1,685% to $13.8M
--------------------------------------------------------------------------------

- Revenue $377,258 for six months ended June 30, 2024, up 55.92% from $241,959 YoY; gross profit $217,190 (+50.48%).
- Shareholders' equity increased to $13,829,445 vs $774,754 at Dec 31, 2023 (+1,685%), largely due to Intramont patent portfolio acquisition in April 2024.
- Company plans to launch compounded ODT GLP-1 inhibitors (Semaglutide/Tirzepatide) for weight loss and hormone therapy MOJO (Enclomiphene/pregnenolone).
- CEO highlights launch of DEA-approved telemedicine operating system.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224032517/0001493152-24-032517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315224032517/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-032517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer